Anti-CD38 antibody for older adults with hard-to-treat ITP
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests an investigational antibody (anti-CD38) for older adults with ITP that hasn't improved with standard treatments. The goal is to see if this antibody can safely raise platelet counts and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years of age or older.
- You have had ITP for at least 3 months.
- Standard treatments like steroids and at least one other therapy (e.g., TPO agonists, rituximab) have not worked or stopped working.
- Your platelet count is consistently below 30,000 per microliter.
- You can take care of yourself (ECOG score 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody treatment (anti-CD38) for children ages 6 to 18 who have had low platelets for at least 3 months and did not improve with steroids. The goal is to see if this treatment can safely raise platelet counts.
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
This trial tests a new drug called anti-CD38 antibody for children and teens with chronic immune thrombocytopenia (ITP) whose platelet counts remain low despite other treatments. It may help increase platelet counts and reduce bleeding risk.
This study compares daratumumab to rituximab for children with primary immune thrombocytopenia (ITP) that hasn't improved with steroids. The goal is to find a better treatment to raise platelet counts and reduce bleeding risk.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.